Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators. Maio M, et al. Among authors: goodman gr. Lancet Oncol. 2018 Apr;19(4):510-520. doi: 10.1016/S1470-2045(18)30106-2. Epub 2018 Feb 21. Lancet Oncol. 2018. PMID: 29477665 Clinical Trial.
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib.
Ascierto PA, Lewis KD, Di Giacomo AM, Demidov L, Mandalà M, Bondarenko I, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Simmons B, Ye C, Hooper G, Wongchenko MJ, Goodman GR, Yan Y, Schadendorf D. Ascierto PA, et al. Among authors: goodman gr. Ann Oncol. 2020 Jan;31(1):153-159. doi: 10.1016/j.annonc.2019.10.002. Ann Oncol. 2020. PMID: 31912791 Free article. Clinical Trial.
Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenib.
Schadendorf D, Di Giacomo AM, Demidov L, Merelli B, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Hong A, Lewis K; BRIM8 Investigators. Schadendorf D, et al. Among authors: goodman gr. Eur J Cancer. 2019 Dec;123:155-161. doi: 10.1016/j.ejca.2019.09.019. Epub 2019 Nov 5. Eur J Cancer. 2019. PMID: 31704549 Free article. Clinical Trial.
A prospective observational safety study of patients with BRAFV 600 -mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study).
Corrie PG, Terheyden P, Ten Tije AJ, Herbst R, Jansen R, Marples M, Debus D, Marconcini R, Blasinska-Morawiec M, Freivogel K, Munson MLG, Goodman GR, Hsu JJ, Sadetsky N, Colburn D, Rutkowski P. Corrie PG, et al. Among authors: goodman gr. Br J Dermatol. 2019 May;180(5):1254-1255. doi: 10.1111/bjd.17465. Epub 2019 Feb 10. Br J Dermatol. 2019. PMID: 30488430 No abstract available.
Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.
Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR. Amaravadi RK, et al. Among authors: goodman gr. Clin Cancer Res. 2015 Dec 1;21(23):5215-21. doi: 10.1158/1078-0432.CCR-15-0469. Epub 2015 Jul 22. Clin Cancer Res. 2015. PMID: 26202952 Free PMC article.
73 results